![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Cipla Limited Mumbai In, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Nevirapine, 017905, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R1-CEP 2007-087 - Rev 02
This Chemical Type CEP, issued on May 18, 2016, remains in force until May 13, 2022, ensuring its reliability within the pharmaceutical industry.
Substance Number 2255 associated with this CEP further emphasizes